Tags

Type your tag names separated by a space and hit enter

Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
Br J Dermatol. 2005 Jul; 153(1):203-5.BJ

Abstract

Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. We successfully treated a patient with multiple L. braziliensis CL lesions acquired in Belize. Liposomal amphotericin B (AmBisome) was given to our patient as an inpatient for seven daily doses of 3 mg kg(-1) day(-1) and then as an outpatient at 3 mg kg(-1) twice weekly for a further three weeks, a total of 40 mg kg(-1). Liposomal amphotericin offers a well-tolerated alternative to pentavalent antimony or amphotericin B deoxycholate for the systemic treatment of New World CL.

Authors+Show Affiliations

Brown M
Department of Infection & Tropical Medicine, Northwick Park Hospital, Harrow, UK. michael.brown@lshtm.ac.uk
Noursadeghi M
No affiliation info available
Boyle J
No affiliation info available
Davidson RN
No affiliation info available

MeSH

AdultAmphotericin BAnimalsAntiprotozoal AgentsHumansLeg DermatosesLeishmania braziliensisLeishmaniasis, CutaneousLiposomesMale

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

16029352

Citation

Brown, M, et al. "Successful Liposomal Amphotericin B Treatment of Leishmania Braziliensis Cutaneous Leishmaniasis." The British Journal of Dermatology, vol. 153, no. 1, 2005, pp. 203-5.
Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153(1):203-5.
Brown, M., Noursadeghi, M., Boyle, J., & Davidson, R. N. (2005). Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. The British Journal of Dermatology, 153(1), 203-5.
Brown M, et al. Successful Liposomal Amphotericin B Treatment of Leishmania Braziliensis Cutaneous Leishmaniasis. Br J Dermatol. 2005;153(1):203-5. PubMed PMID: 16029352.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. AU - Brown,M, AU - Noursadeghi,M, AU - Boyle,J, AU - Davidson,R N, PY - 2005/7/21/pubmed PY - 2005/10/26/medline PY - 2005/7/21/entrez SP - 203 EP - 5 JF - The British journal of dermatology JO - Br J Dermatol VL - 153 IS - 1 N2 - Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. We successfully treated a patient with multiple L. braziliensis CL lesions acquired in Belize. Liposomal amphotericin B (AmBisome) was given to our patient as an inpatient for seven daily doses of 3 mg kg(-1) day(-1) and then as an outpatient at 3 mg kg(-1) twice weekly for a further three weeks, a total of 40 mg kg(-1). Liposomal amphotericin offers a well-tolerated alternative to pentavalent antimony or amphotericin B deoxycholate for the systemic treatment of New World CL. SN - 0007-0963 UR - https://www.unboundmedicine.com/medline/citation/16029352/Successful_liposomal_amphotericin_B_treatment_of_Leishmania_braziliensis_cutaneous_leishmaniasis_ DB - PRIME DP - Unbound Medicine ER -